What is First Tracks Biotherapeutics Inc's net change in cash?

First Tracks Biotherapeutics Inc (TRAX) reported net change in cash of $10.27M in Q1 2026.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Screener

BKBK

$1.53B-46.1%

VeradermicsMANE

$146.65M+810%

GPA

General Purpose Acquisition Corp.GPAC

-$2.24M-432%

Polaryx Therapeutics, Inc.PLYX

13,050,000%-102,425,000pp

Schering-PloughSGP

$142.54M+242%

Dycom IndustriesDY

-$170.34M-122%

Reported directly by First Tracks Biotherapeutics Inc in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.

(in thousands)	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
CASH FLOWS FROM FINANCING ACTIVITIES:
Net parent investment	7,851	5,716
Net cash provided by financing activities	7,851	5,716
Net increase (decrease) in cash and cash equivalents	10,273	(24,443)
Cash and cash equivalents, beginning of period	238,196	123,080
Cash and cash equivalents, end of period	$248,469	$98,637
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Non-cash investing and financing activities:

Item 1. Combined Financial Statements.

What is First Tracks Biotherapeutics Inc's net change in cash?: First Tracks Biotherapeutics Inc (TRAX) reported net change in cash of $10.27M in Q1 2026.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Connect your AI assistant and compare it to peers, right in your chat.